MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

15.6 1.89

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.24

Max

15.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

6M

Pardavimai

162M

P/E

Sektoriaus vid.

75.25

40.527

Pelno marža

3.676

Darbuotojai

1,811

EBITDA

-5M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+35.3% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.6B

Ankstesnė atidarymo kaina

13.71

Ankstesnė uždarymo kaina

15.6

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-02 17:03; UTC

Pagrindinės rinkos jėgos

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2025-07-02 15:18; UTC

Pagrindinės rinkos jėgos

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2025-07-02 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-02 23:45; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-07-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2025-07-02 21:01; UTC

Įsigijimai, susijungimai, perėmimai

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2025-07-02 21:01; UTC

Įsigijimai, susijungimai, perėmimai

AT&T and TPG Close DIRECTV Transaction

2025-07-02 20:26; UTC

Uždarbis

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2025-07-02 20:22; UTC

Rinkos pokalbiai

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2025-07-02 20:13; UTC

Rinkos pokalbiai

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2025-07-02 19:09; UTC

Rinkos pokalbiai

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2025-07-02 19:08; UTC

Rinkos pokalbiai

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2025-07-02 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2025-07-02 18:08; UTC

Rinkos pokalbiai

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2025-07-02 17:06; UTC

Įsigijimai, susijungimai, perėmimai

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2025-07-02 17:05; UTC

Įsigijimai, susijungimai, perėmimai

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2025-07-02 17:04; UTC

Įsigijimai, susijungimai, perėmimai

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2025-07-02 17:04; UTC

Įsigijimai, susijungimai, perėmimai

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2025-07-02 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2025-07-02 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2025-07-02 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-02 16:20; UTC

Rinkos pokalbiai

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2025-07-02 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-02 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-02 16:11; UTC

Rinkos pokalbiai

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2025-07-02 16:09; UTC

Rinkos pokalbiai

Gold Futures Rise, Recouping Some Losses -- Market Talk

2025-07-02 15:59; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2025-07-02 15:17; UTC

Rinkos pokalbiai

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2025-07-02 15:08; UTC

Rinkos pokalbiai

Luxury Sector Should Report a Slowdown -- Market Talk

2025-07-02 15:00; UTC

Įsigijimai, susijungimai, perėmimai

Glencore: Merger of Viterra With Bunge Global Closed

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

35.3% į viršų

12 mėnesių prognozė

Vidutinis 20.85 USD  35.3%

Aukščiausias 27 USD

Žemiausias 14.7 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.